A Phase II, Multicenter, Open-Label Study of EGF816 in Combination with Nivolumab in Adult Patients with EGFR mutated NSCLC and of INC280 in Combination with Nivolumab in Adult Patients with cMet Positive NSCLC
A Phase II, Multicenter, Open-Label Study of EGF816 in Combination with Nivolumab in Adult Patients with EGFR mutated NSCLC and of INC280 in Combination with Nivolumab in Adult Patients with cMet Positive NSCLC
Press Ctrl +⌘ + to increase font size.
Press Ctrl -⌘ - to decrease font size.
Press Ctrl 0⌘ 0 to reset font size.